regeneron

Regeneron stock touches 52-week low at $785.31

Investing.com - 14 Nov 2024
Regeneron stock touches 52-week low at $785.31  ...

• More

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

Yahoo Finance - 13 Nov 2024
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease  ...

• More

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day

MarketWatch - 11 Nov 2024
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day  ...

• More

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

GlobeNewswire - 15 Nov 2024
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria  ...

• More

Regeneron shares drop as higher-dose Eylea drug misses sales estimates

Reuters - 31 Oct 2024
Regeneron shares drop as higher-dose Eylea drug misses sales estimates  ...

• More

Regeneron head says weight-loss drugs could cause ‘more harm than good’

Financial Times - 05 Oct 2024
Regeneron head says weight-loss drugs could cause ‘more harm than good’  ...

• More

28 Analysts Have This To Say About Regeneron Pharmaceuticals

Benzinga - 14 Nov 2024
28 Analysts Have This To Say About Regeneron Pharmaceuticals  ...

• More

Regeneron's Eylea HD makes progress but doesn't dent the momentum of Roche's Vabysmo

FiercePharma - 31 Oct 2024
Regeneron's Eylea HD makes progress but doesn't dent the momentum of Roche's Vabysmo  ...

• More

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

Business Wire - 01 Nov 2024
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors  ...

• More

Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’

TipRanks - 14 Nov 2024
Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’  ...

• More

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom

Investor's Business Daily - 31 Oct 2024
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom  ...

• More

Regeneron Reports Mixed Q3 Sales as Eylea Franchise Remains Under Pressure

BioSpace - 01 Nov 2024
Regeneron Reports Mixed Q3 Sales as Eylea Franchise Remains Under Pressure  ...

• More

Regeneron Announces Investor Conference Presentations

Yahoo Finance - 11 Nov 2024
Regeneron Announces Investor Conference Presentations  ...

• More

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day

MarketWatch - 12 Nov 2024
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day  ...

• More

Regeneron initiated with an Outperform at Wolfe Research

TipRanks - 14 Nov 2024
Regeneron initiated with an Outperform at Wolfe Research  ...

• More

Regeneron loses bid to block Amgen's Eylea biosimilar launch in US

Reuters - 22 Oct 2024
Regeneron loses bid to block Amgen's Eylea biosimilar launch in US  ...

• More

We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease

Yahoo Finance - 10 Nov 2024
We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease  ...

• More

American upgraded, Regeneron initiated: Wall Street’s top analyst calls

TipRanks - 14 Nov 2024
American upgraded, Regeneron initiated: Wall Street’s top analyst calls  ...

• More

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?

Yahoo Finance - 31 Oct 2024
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?  ...

• More